MX2024011358A - Moleculas bifuncionales para degradar proteinas circulantes - Google Patents

Moleculas bifuncionales para degradar proteinas circulantes

Info

Publication number
MX2024011358A
MX2024011358A MX2024011358A MX2024011358A MX2024011358A MX 2024011358 A MX2024011358 A MX 2024011358A MX 2024011358 A MX2024011358 A MX 2024011358A MX 2024011358 A MX2024011358 A MX 2024011358A MX 2024011358 A MX2024011358 A MX 2024011358A
Authority
MX
Mexico
Prior art keywords
mif
igg
conditions
bifunctional molecules
circulating proteins
Prior art date
Application number
MX2024011358A
Other languages
English (en)
Spanish (es)
Inventor
David Spiegel
David Caianiello
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/695,259 external-priority patent/US20230097887A1/en
Application filed by Univ Yale filed Critical Univ Yale
Publication of MX2024011358A publication Critical patent/MX2024011358A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/08—Polyoxyalkylene derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024011358A 2022-03-15 2024-09-13 Moleculas bifuncionales para degradar proteinas circulantes MX2024011358A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/695,259 US20230097887A1 (en) 2018-04-09 2022-03-15 Bi-functional Molecules to Degrade Circulating Proteins
PCT/US2023/064436 WO2023178179A2 (en) 2022-03-15 2023-03-15 Bi-functional molecules to degrade circulating proteins

Publications (1)

Publication Number Publication Date
MX2024011358A true MX2024011358A (es) 2025-01-09

Family

ID=88024435

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011358A MX2024011358A (es) 2022-03-15 2024-09-13 Moleculas bifuncionales para degradar proteinas circulantes

Country Status (8)

Country Link
EP (1) EP4493220A2 (https=)
JP (1) JP2025509736A (https=)
KR (1) KR20250004953A (https=)
CN (1) CN119212726A (https=)
AU (1) AU2023234543A1 (https=)
IL (1) IL315581A (https=)
MX (1) MX2024011358A (https=)
WO (1) WO2023178179A2 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
WO2019199621A1 (en) * 2018-04-09 2019-10-17 Yale University Bi-functional molecules to degrade circulating proteins
EP3773727A4 (en) * 2018-04-09 2022-05-04 Yale University BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS
AU2019404061A1 (en) * 2018-12-19 2021-07-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules for lysosomal targeting and related compositions and methods
WO2021155317A1 (en) * 2020-01-31 2021-08-05 Avilar Therapeutics, Inc. Asgpr-binding compounds for the degradation of extracellular proteins

Also Published As

Publication number Publication date
JP2025509736A (ja) 2025-04-11
WO2023178179A3 (en) 2023-10-26
AU2023234543A1 (en) 2024-10-03
CN119212726A (zh) 2024-12-27
WO2023178179A2 (en) 2023-09-21
KR20250004953A (ko) 2025-01-08
EP4493220A2 (en) 2025-01-22
IL315581A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
Khandpur et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis
CL2023002108A1 (es) Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.
Siegmund et al. Serum amyloid A induces inflammation, proliferation and cell death in activated hepatic stellate cells
BR112021021224A2 (pt) Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo
JOP20210154B1 (ar) مثبطات kif18a
Kiron et al. Recognition of purified beta 1, 3/1, 6 glucan and molecular signalling in the intestine of Atlantic salmon
Launay et al. Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome
BRPI0618399A2 (pt) região de ligação de antìgeno isolada que é especìfica para cd38, anticorpo isolado ou um fragmento funcional do mesmo que é especìfico para cd38, anticorpo isolado ou um fragmento funcional do mesmo, imunoglobulina isolada, cadeia pesada variável de uma região de ligação de antìgeno isolada, cadeia leve variável de uma região de ligação de antìgeno isolada, seqüência isolada de ácido nucléico, seqüência de ácido nucléico que codifica uma cadeia pesada variável de uma região de ligação de antìgeno isolada, seqüência de ácido nucléico, vetor, célula isolada, composição farmacêutica, uso da composição farmacêutica, método de indução de mortandade especìfica das células de tumor que expressam cd38, método de detecção da mortandade especìfica das células de tumor que expressam cd38, método de detecção da presença de cd38 em um tecido ou em célula de origem de miniporco, método de detecção de cd38 em um eritrócito que expressa cd38 e composição de diagnóstico
BR112022007720A2 (pt) Anticorpos humanizados para ligante 1a tnf-like (tl1a) e seus usos
BR112017005110A2 (pt) anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
BR112022015002A2 (pt) Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico
BR112023023578A2 (pt) Composto, composição farmacêutica compreendendo o composto e método de tratamento de uma leucemia aguda
BR112021022089A2 (pt) Materiais e métodos para modulação da imunidade mediada por células t
Zhao et al. CRISPR-mediated Sox9 activation and RelA inhibition enhance cell therapy for osteoarthritis
Hu et al. Effects of arsenic trioxide on INF-gamma gene expression in MRL/lpr mice and human lupus
Saldanha et al. Anti-inflammatory and central and peripheral anti-nociceptive activities of α-asarone through the inhibition of TNF-α production, leukocyte recruitment and iNOS expression, and participation of the adenosinergic and opioidergic systems: AA Saldanha et al.
Nakamura et al. HIF-1α and MIF enhance neutrophil-driven type 3 immunity and chondrogenesis in a murine spondyloarthritis model
Saha An overview of therapeutic targeting of Nrf2 signaling pathway in rheumatoid arthritis
MX2024011358A (es) Moleculas bifuncionales para degradar proteinas circulantes
Jarmakiewicz-Czaja et al. The role of genetic and epigenetic regulation in intestinal fibrosis in inflammatory bowel disease: A descending process or a programmed consequence?
Kusza et al. Activity-based proteomic identification of the S-thiolation targets of ajoene in MDA-MB-231 breast cancer cells
BR112022020716A2 (pt) Anticorpos anti-tumor associados ao antígeno e usos dos mesmos
Dekker et al. Modulation of brain transcriptome by combined histone deacetylase inhibition and plasma treatment following traumatic brain injury and hemorrhagic shock
CY1124553T1 (el) Γελη θεραπειας πληγων που μπορει να λαμβανεται με συνδυασμο πλουσιου σε αιμοπεταλια πλασματος με αυτολογα παραγομενη θρομβινη
CO2023016037A2 (es) Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos